GAC - IMO we will see more and more attention all over the world as we get closer to full data presentations. I think I remember DM saying patients from 18 countries have participated in trials that RVX-208 has had so far. That should equal patients, doctors, clinicians, politicians and friends and acquaintances of all of the above in all of those countries plus Canada and the US investors that have at least heard of us.

Paul you have your work cut out bringing this all together over the next number of months.

tada